Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Cancer Lett. 2018 May 30;431:142–149. doi: 10.1016/j.canlet.2018.05.047

Fig. 6. CHK inhibitors sensitize ex vivo hypoxic tumor cells to ionizing irradiation.

Fig. 6

The hypoxic (EGFP+) and non-hypoxic (EGFP−) tumor cells sorted from xenograft tumors and cultured in vitro as described in Figure 5. (A) Tumor cells were treated with the CHK inhibitor AZD7762 at 20 nM for 24 hrs and then plated at 1,000 cells/well (n=6) in 6-well plates for clonogenic assay with vehicle-treated cells as control. (B) Tumor cells were treated with or without AZD7762 at 20 nM for 24 hrs and then irradiated at 5 Gy X-ray. The irradiated cells were then plated at 5,000 cells/well (n=6) in 6-well plates for clonogenic survival assay.

HHS Vulnerability Disclosure